

**Documents**

>> Questel Plus

WPIL IFIPAT >> IMAGINEO

1 - EP812858/PN/XPXN - 1

Terme(s) absent(s) de l'index/XPXN-WPIL : EP812858  
Terme(s) absent(s) de l'index/PN-IFIPAT : EP812858  
Terme(s) absent(s) de l'index/XPXN-IFIPAT : EP812858

WPIL 1  
IFIPAT 0

\*\* Question 1, nombre de reponses 1

Doc. 1 de qu 1 depuis WPIL au format MAX

BEST AVAILABLE COPY

**1/1 WPIL**

**Titre**

Pure, non-immunogenic Factor=VIII composition preparation - using 2-stage viral inactivation of Factor=VIII solution by treatment with phosphate and detergent followed by heating, used for treating haemophilia

**Données de publication**

**N° publication**

EP-812858 A1 19971217 DW1998-04 C07K-014/755 Ger 16p \* AP: 1997EP-0109314 19970609 DSR:

AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DE19623293 A1 19971218 DW1998-05 C07K-014/755 12p AP: 1996DE-1023293 19960611

CZ9701774 A3 19971217 DW1998-07 C07K-014/755 AP: 1997CZ-0001774 19970609

HU9700987 A2 19980302 DW1998-21 A61K-035/16 AP: 1997HU-0000987 19970603

DE19623293 C2 19981022 DW1998-46 C07K-014/755 AP: 1996DE-1023293 19960611

N° priorité 1996DE-1023293 19960611

Nb. pays couverts 20

Nb. publications 5

**CIB**

A61K-035/16 C07K-014/755 A61K-038/37 C07K-001/18 C07K-001/34

**Résumé**

**Basic**

EP-812858 A Preparation of a non-immunogenic composition (I) containing Factor VIII (F8) comprises:

(a) treatment of a solution of F8 with tri-(n-butyl) phosphate (TNBP) and detergent, and

(b) heat treatment of a freeze-dried material containing F8 at 100 deg. C for 15-120 minutes, such that the residual moisture content after the heat treatment is 0.3-1.8 wt.%.  
Also claimed is (I).

USE - F8 is used for treating haemophilia.

ADVANTAGE - (I) containing highly pure, doubly virus-inactivated F8 can be obtained from human blood plasma using a 2-stage virus inactivation and purification process involving no use of stabilisers.

Enveloped and non-enveloped viruses are effectively inactivated. Typically the HIV-1 reduction factor (log 10) is > 16.2. Heat treatment under the present conditions causes no significant activity loss.

F8 is typically enriched by a factor of 104 compared with the starting plasma. (Dwg.0/3)

**Déposant & Inventeur(s)**

**Déposant**

(BIOT) BIOTEST PHARMA GMBH

**Inventeur(s)**

BUCCI E; DICHELTMULLER H; KLOFT M; KOTITSCHKE R; LOEBNAU W; OTT G; RUDNICK D;  
DICHELTMUELLER H

**Codes d'accès**

Numéro 1998-034929 [04]

No. Sec. C1998-011842

**Codes**

Codes manuels CPI: B04-H19 B14-F08 D05-H13 D05-H17A

Classes Derwent B04 D16

Codes de mise à jour

Code maj Basic 1998-04